SHOP BEST SELLERS
Shop our best selling products
Type: Performance Supplements
Protein Powder
Type: Performance Supplements
Electrolytes - Stick Packs
Type: Performance Supplements
Electrolytes
Type: Performance Supplements
Creatine Monohydrate
Type: Core Supplements
Source Magnesium
Type: Core Supplements
Vitamin D3 & K2
Type: Body Essentials
Raw Elements Shampoo
Type: Body Essentials
Raw Elements Conditioner
Type: Body Essentials
Raw Elements Tallow Soap (Lemongrass)
Type: Performance Supplements
Raw Honey
Type: Body Essentials
Raw Tallow Sun Balm
★★★★★ 1,000+ 5 Star Reviews
Pure ingredients
Raw ingredients. Ancient wisdom. Modern results. Every product contains only what nature intended:
- Grass-fed tallow rich in bioavailable nutrients
- Raw honey and adaptogenic herbs in their purest form
- Regeneratively sourced proteins, never denatured
- Zero synthetic additives or lab-made fillers
Small-batch wellness our ancestors would recognize. Because when you honor nature's integrity, your body knows the difference.
Purely Natural, Perfectly You
Let customers speak for us
Love it
The best protein powder I have ever tried
The best electrolytes I ever tried
It's nice and smells really good.
used on baby
Great product
Best Shampoo ever made! Makes my hair lush and thicker! This shampoo is top notch and a must have!
Love the smell
Always looking for a clean alternative for supplements. Great Taste. Excited to try other flavors.
I’ve used the shampoo & conditioner 3 times now and my hair is so soft, manageable and clean! Lovin’ it
Started using this product recently and so far I love it. Everything comes as listed, smells great and I feel like I’m washing my hair with a clean product. Can’t beat it.
HELLO EVERYONE.
Natural herbs have cured so many illness that drugs and injection cant cure. I''ve seen the great importance of natural herbs and the wonderful work they have done in people lives. i read testimonies online how they were cured of herpes, HIV, diabetics, cancer etc by Dr. Enosetale's herbal medicine, so i decided to contact him because i know nature has the power to heal anything. I was diagnosed with herpes for the past 9 months but Dr.Enosetale cured me with his herbs and i referred my aunt and her husband to him immediately because they were both suffering from herpes but they were cured too. Contact Dr.Enosetale via email on: dr.enosetale667@ gmail.com Whatsap no: +2347031966178thank you doc
HELLO EVERYONE.
Natural herbs have cured so many illness that drugs and injection cant cure. I''ve seen the great importance of natural herbs and the wonderful work they have done in people lives. i read testimonies online how they were cured of herpes, HIV, diabetics, cancer etc by Dr. Enosetale's herbal medicine, so i decided to contact him because i know nature has the power to heal anything. I was diagnosed with herpes for the past 9 months but Dr.Enosetale cured me with his herbs and i referred my aunt and her husband to him immediately because they were both suffering from herpes but they were cured too. Contact Dr.Enosetale via email on: dr.enosetale667@ gmail.com Whatsap no: +2347031966178thank you doc
HELLO EVERYONE.
Natural herbs have cured so many illness that drugs and injection cant cure. I''ve seen the great importance of natural herbs and the wonderful work they have done in people lives. i read testimonies online how they were cured of herpes, HIV, diabetics, cancer etc by Dr. Enosetale's herbal medicine, so i decided to contact him because i know nature has the power to heal anything. I was diagnosed with herpes for the past 9 months but Dr.Enosetale cured me with his herbs and i referred my aunt and her husband to him immediately because they were both suffering from herpes but they were cured too. Contact Dr.Enosetale via email on: dr.enosetale667@ gmail.com Whatsap no: +2347031966178thank you doc
HELLO EVERYONE.
Natural herbs have cured so many illness that drugs and injection cant cure. I''ve seen the great importance of natural herbs and the wonderful work they have done in people lives. i read testimonies online how they were cured of herpes, HIV, diabetics, cancer etc by Dr. Enosetale's herbal medicine, so i decided to contact him because i know nature has the power to heal anything. I was diagnosed with herpes for the past 9 months but Dr.Enosetale cured me with his herbs and i referred my aunt and her husband to him immediately because they were both suffering from herpes but they were cured too. Contact Dr.Enosetale via email on: dr.enosetale667@ gmail.com Whatsap no: +2347031966178thank you doc
Why Purishh?
Pure Ingredients
Handpicked and ethically sourced from trusted, natural farms.
Effective Results
Each product is designed to protect, nourish, and enhance your skin’s natural balance.
Holistic Wellness
Embrace a balanced lifestyle with supplements and creams that work in harmony with your body.
Frequently Asked Question
What makes Purishh products different from conventional supplements or skincare?
What makes Purishh products different from conventional supplements or skincare?
Purishh’s mission is to return to the raw, unprocessed power of nature. Every product is formulated with 100 % natural ingredients and no synthetic preservatives, fillers, or dyes. For example, the Raw Honey Butter contains whipped Wagyu beef tallow, cold‑pressed olive and coconut oils, mango butter, raw honey and beeswax – it moisturizes deeply and can even replace conventional lotion. The Raw Tallow Sunbalm uses grass‑fed tallow, non‑nano zinc oxide and organic oils to provide mineral sun protection while nourishing the skin. Purishh’s Protein Powder combines grass‑fed whey and hydrolyzed collagen with organic superfoods to deliver 26 g of easily digestible protein with zero added sugar. Across their range, Purishh keeps ingredient lists short and transparent, using only what is necessary to support health and well‑being.
Are Purishh’s ingredients ethically and sustainably sourced?
Are Purishh’s ingredients ethically and sustainably sourced?
Yes. The founders emphasize sustainable sourcing and ethical treatment of animals and land. Tallow for the skincare range is hand‑sourced from 100 % grass‑fed, Wagyu, halal cattle in New Zealand, ensuring humane slaughter and optimal nutrient quality. Olive and coconut oils are single‑origin, cold‑pressed. The whey in Purishh protein powder comes from grass‑fed cows raised without hormones or antibiotics, and the collagen is hydrolyzed for better absorption. These practices mean customers receive products that are both pure and sustainable.
Why does Purishh use beef tallow in its skincare products?
Why does Purishh use beef tallow in its skincare products?
Grass‑fed beef tallow is biocompatible with human skin; its fatty‑acid profile closely resembles natural sebum, so it’s absorbed efficiently. Properly rendered tallow is a vitamin powerhouse, naturally supplying vitamins A, D, E, and K that support cell turnover, immune function, and antioxidant protection. Tallow also contains oleic, stearic and palmitic acids that strengthen the skin’s barrier, calm inflammation and maintain moisture. Grass‑fed tallow offers a high concentration of conjugated linoleic acid (CLA), an anti‑inflammatory fatty acid. These nutrients collectively help Purishh’s Raw Honey Butter and Raw Tallow Sunbalm to moisturize, nourish and protect the skin without clogging pores or causing irritation.
How is Purishh protein powder different, and why is it easy to digest?
How is Purishh protein powder different, and why is it easy to digest?
Many conventional protein powders use cheap sources and add artificial thickeners or sweeteners that cause bloating and digestive discomfort. Purishh starts with grass‑fed whey processed via cold‑filtration, which preserves natural enzymes and bioactive peptides that aid digestion. It also adds hydrolyzed bovine collagen to support joints, skin and gut health. The powder uses organic monk fruit for sweetness and contains no carrageenan, gums, sucralose or artificial preservatives, so it mixes smoothly and is gentle on the stomach. Each serving provides 26 g of complete protein with only 1 g of fat and zero sugar, making it suitable for keto, gluten‑free and non‑GMO diets.
What are Purishh Electrolytes, and how do they support hydration?
What are Purishh Electrolytes, and how do they support hydration?
Purishh’s Electrolytes formula offers clean hydration without the artificial colors and preservatives found in many sports drinks. Each serving includes over 800 mg of unrefined Himalayan salt, providing sodium and trace minerals, plus magnesium malate and potassium chloride. Organic fruit powders (raspberry or lemon‑lime) and monk fruit sweetener give a natural flavor without sugar. The formula helps replenish electrolytes lost through exercise, supports muscle function, and is keto‑friendly.
What is Raw Shilajit, and how should it be used?
What is Raw Shilajit, and how should it be used?
Raw Shilajit is a resin harvested from high‑altitude Himalayan rocks. It forms from decomposed plant material and is rich in minerals and fulvic acid. Traditionally used as an adaptogen, Shilajit helps boost energy, improve stamina and support overall health. Purishh provides 100 % pure Himalayan shilajit. Users typically dissolve a pea‑sized amount in warm water, tea or milk. Due to its potent minerals, start with a small dose and consult a healthcare professional if you have existing medical conditions.
What is the Ishh Leaky Gut Protocol?
What is the Ishh Leaky Gut Protocol?
The Ishh Leaky Gut Protocol is a step‑by‑step program designed to help restore gut health naturally. It includes dietary recommendations, lifestyle tips and natural supplements to support the intestinal lining. The protocol focuses on removing irritants, replenishing beneficial bacteria and repairing the gut barrier. It is not a medical treatment, so customers with chronic digestive issues should consult a healthcare professional before starting.
How should I store Purishh products?
How should I store Purishh products?
Store supplements and protein powders in a cool, dry place away from direct sunlight. Skincare products like Raw Honey Butter and Raw Tallow Sunbalm are natural and free from artificial stabilizers; keeping them at room temperature helps maintain texture. If you live in a hot climate, refrigerating tallow‑based balms can prevent melting. Always use clean hands or a spatula to avoid introducing bacteria.
When will my order ship, and how long will delivery take?
When will my order ship, and how long will delivery take?
Purishh asks customers to allow 2–3 business days for processing and production before an order ships. Once dispatched, average transit times are 7–10 business days; however, natural disasters, holidays and weather can cause delays. Free standard shipping is offered on orders over US$150 (or equivalent), and shipping costs for smaller orders are calculated at checkout. Purishh cannot guarantee exact delivery dates because delivery is ultimately the responsibility of the shipping carrier.
Can I subscribe and save on regular purchases?
Can I subscribe and save on regular purchases?
Yes. Purishh offers a subscription program for products like protein powder. Subscribing gives 10 % off the regular price, and you can choose delivery intervals (e.g., monthly). Subscriptions auto‑renew, but you may skip or cancel at any time through your account.
Are Purishh products allergen‑free or suitable for special diets?
Are Purishh products allergen‑free or suitable for special diets?
Purishh formulates products without common synthetic additives, but some items may contain potential allergens. The protein powder contains whey (a dairy product) and collagen derived from bovine sources; it is unsuitable for vegans or those with dairy allergies. The Electrolytes formula is gluten‑free, sugar‑free and keto‑friendly. Always review ingredient lists carefully and consult your healthcare provider if you have specific allergies or dietary restrictions.
Where are Purishh products made?
Where are Purishh products made?
Purishh sources ingredients globally, such as New Zealand Wagyu tallow and Himalayan shilajit, but manufactures products in small batches under rigorous quality control. By keeping production small and hands‑on, Purishh can maintain freshness and ensure every batch meets the highest standards.
Pür Insights
Bone Density After Menopause: Where D3, K2, and Protein Fit
Bone Density After Menopause: Where D3, K2, and Protein Fit Three nutrients dominate the conversation about bone health after menopause. All three have more complicated evidence than the marketing suggests, and the complications run in different directions. One has been substantially undercut by large randomized trials and now carries formal recommendations against its routine use for this purpose. One has genuinely mixed trial results. And one spent decades being blamed for harming bone before the research reversed, and now has modestly positive support. This post covers what the evidence actually shows for each, where the honest limits sit, and what the research consistently identifies as mattering more than any of them. What happens to bone after menopause Bone is living tissue in continuous turnover, with osteoclasts breaking down old bone and osteoblasts building new bone. Estrogen plays a regulatory role in keeping that cycle balanced. When estrogen declines through the menopausal transition, resorption begins outpacing formation, and bone density falls. The result is an accelerated loss that is specific to this period rather than a general feature of aging. It is also the reason bone health becomes a more prominent concern for women in midlife than for men of the same age. Osteoporosis itself is a clinical diagnosis with defined criteria and established medical treatments. Nothing in this post addresses treatment, and anyone with diagnosed osteoporosis or osteopenia should be working with a physician rather than substituting nutritional strategies for medical care. What follows is about what nutrition contributes, which is a narrower question. Vitamin D: what the large trials found This is where the evidence has shifted most dramatically, and where the gap between current guidance and popular assumption is widest. The VITAL trial is the central piece of evidence. Published by LeBoff and colleagues in the New England Journal of Medicine in 2022, volume 387, issue 4, pages 299 to 309, it was an ancillary study of a two-by-two factorial randomized controlled trial testing supplemental vitamin D3 at 2,000 IU per day against placebo. The ancillary study included 25,871 participants with a mean age of 67, of whom 51 percent were women, drawn from all 50 US states. Participants were men aged 50 and older and women aged 55 and older, and were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis. The primary endpoints were incident total, nonvertebral, and hip fractures, reported on annual questionnaires and adjudicated by centralized medical record review. The finding: vitamin D3 supplementation did not result in a significantly lower risk of fractures than placebo. One detail is worth emphasizing because it preempts the most common objection. The absence of benefit persisted even among participants with lower baseline 25-hydroxyvitamin D concentrations, below 20 nanograms per millilitre. The null result was not simply an artifact of studying an already-replete population. These findings were corroborated by the DO-HEALTH study in Europe and the D-Health trial in Australia, both of which similarly found no significant reduction in fracture risk among vitamin D-replete older adults. The accompanying editorial by Cummings and Rosen, published in the same issue, was titled "VITAL findings: A decisive verdict on vitamin D supplementation." What the guidelines now say The regulatory and professional response has followed the evidence, and it is more direct than most people realize. The US Preventive Services Task Force, in its 2024 draft recommendation, issued a grade D statement against vitamin D supplementation for the primary prevention of fractures and falls in community-dwelling adults. A grade D recommendation means the task force recommends against the service, having concluded there is no net benefit or that harms outweigh benefits. The stated reasoning cited potential harms including nephrolithiasis, combined with the absence of net benefit observed in trials such as VITAL, in a largely vitamin D-sufficient population. The 2024 Endocrine Society Clinical Practice Guideline similarly advises against empiric vitamin D supplementation in healthy adults younger than 75, and discourages routine screening of serum 25-hydroxyvitamin D levels. Both bodies maintain that supplementation remains appropriate for specific subgroups, including adults aged 75 and older, pregnant individuals, and those at elevated metabolic risk such as people with prediabetes. The scope of these recommendations matters and should not be overstated in either direction. They address primary prevention in community-dwelling adults without known osteoporosis or established deficiency. They do not address people with diagnosed deficiency, diagnosed osteoporosis, or the specific subgroups named above. Vitamin D remains genuinely necessary for calcium absorption, and correcting a genuine deficiency remains a legitimate clinical intervention. What has changed is the case for taking vitamin D as a fracture-prevention measure if you are a generally healthy adult without deficiency. That case has weakened substantially. Vitamin K2: mixed, as covered previously We have written about vitamin K2 and bone in detail elsewhere, including the trials that disagree, so this will be brief. The headline evidence is the Knapen trial, published in Osteoporosis International in 2013, a three-year randomized controlled trial in 244 postmenopausal women aged 55 to 65 taking 180 micrograms of MK-7 daily. It found significantly decreased age-related decline in bone mineral density at the lumbar spine and femoral neck, though not at the total hip, and reduced vertebral height loss. It sits alongside other rigorous trials that found no significant benefit, including a 2010 trial by Emaus and colleagues in 334 Norwegian women using 360 micrograms of MK-7 for one year, a 2020 three-year trial in 142 postmenopausal women with osteopenia using 375 micrograms daily that found no difference from placebo at any measured site, and work by Binkley and colleagues that confirmed vitamin K reduced undercarboxylated osteocalcin as expected while producing no detectable change in bone turnover, density, or geometry. The mechanism, involving K2-dependent carboxylation of osteocalcin, is well established at the biochemical level. Whether that translates into measurable bone outcomes remains genuinely contested, with well-designed trials reaching opposing conclusions. Protein: the reversal worth knowing about Protein has the most interesting history of the three, because the prevailing view was wrong for decades in a specific and identifiable way. The acid-ash hypothesis held that dietary protein, particularly animal protein, generates an acid load that the body neutralizes by drawing calcium from bone, thereby causing bone loss. It was widely accepted, widely taught, and drove recommendations to limit protein intake for bone health. A series of analyses by Fenton and colleagues systematically dismantled it. Their 2009 meta-analysis in the Journal of Bone and Mineral Research, volume 24, pages 1835 to 1840, examined the effect of the acid-ash hypothesis on calcium balance. Their 2011 paper in Nutrition Journal, volume 10, article 41, conducted a causal assessment of dietary acid load and bone disease applying Hill's epidemiological criteria for causality. The hypothesis did not survive that scrutiny, and a subsequent meta-analysis found no evidence for a protective effect of an alkaline diet on bone health. What replaced it is a modestly positive picture, though one with real internal tension worth reporting honestly. An expert consensus paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation, published in Osteoporosis International in 2018, concluded that in older people with osteoporosis, higher protein intake at or above 0.8 grams per kilogram of body weight per day is associated with higher bone mineral density, a slower rate of bone loss, and reduced risk of hip fracture, provided calcium intake is adequate. The Health, Aging, and Body Composition Study found that higher protein intake was associated with lower vertebral fracture risk, with the upper protein tertile, averaging 1.1 grams per kilogram per day, showing 1.8 to 6.0 percent higher mean baseline bone mineral density. The authors concluded that the lower end of the acceptable macronutrient distribution range and the 0.8 gram per kilogram RDA may be suboptimal for bone mineral density preservation in older adults. A meta-analysis of cross-sectional studies attributed a 2 to 4 percent increase in bone mineral density to protein intake above the RDA. Here is the tension. A systematic review and meta-analysis conducted for the National Osteoporosis Foundation and published in the American Journal of Clinical Nutrition pooled six randomized controlled trials and found no difference between higher and lower protein intake on femoral neck bone mineral density, with a pooled mean percentage change of negative 0.14 percent, a 95 percent confidence interval of negative 0.60 to 0.32, and zero statistical heterogeneity. So the observational and cohort evidence associates higher protein intake with better bone outcomes, particularly fracture risk, while the randomized trial evidence on bone mineral density specifically shows no difference. That pattern can reflect several things: that protein affects fracture risk through pathways other than density, such as muscle mass and fall prevention; that observational associations are confounded by overall dietary quality; or that the RCTs were too short to detect changes in a slow-moving outcome. The honest reading: protein is not harmful to bone, which was the older belief and was wrong. The evidence that higher intake actively improves bone density in randomized trials is absent. The evidence associating it with lower fracture risk is real but observational. What the research consistently identifies as mattering more Across this literature, one intervention appears more consistently than any nutrient, and it is not a supplement. Weight-bearing and resistance exercise applies mechanical load to bone, and bone responds to mechanical load by remodelling. This is the same principle underlying why astronauts lose bone density in microgravity and why the loading history of a limb affects its density. It is a direct stimulus rather than a supporting input. There is also a compounding factor specific to fractures rather than density. Most osteoporotic fractures occur as a result of falls. Muscle strength, balance, and reaction time determine fall risk, and all three respond to resistance and balance training. A person with stronger legs and better balance falls less often, and fracture risk is a function of both bone fragility and the frequency of the events that stress it. This is why interventions combining resistance training with nutritional support consistently outperform nutritional support alone in the broader literature on musculoskeletal outcomes in older adults, a pattern we have examined in detail elsewhere. The honest hierarchy Putting this together for bone health after menopause specifically. Weight-bearing and resistance exercise has the most direct mechanism and the strongest case, both for bone loading and for reducing the falls that convert low bone density into actual fractures. Adequate calcium intake remains a foundational requirement, and the ESCEO and IOF protein consensus explicitly conditions its findings on adequate calcium. Adequate protein is supportive and no longer suspect. The old acid-ash concern has been overturned. Higher intake associates with lower fracture risk in cohort data, while randomized trials show no bone density difference. The recommendations at or above 0.8 grams per kilogram per day are reasonable, and overlap with the intake ranges recommended for muscle preservation. Vitamin D remains necessary for calcium absorption, and correcting a genuine deficiency remains legitimate. Taking it as a fracture-prevention measure without deficiency is not supported by VITAL, DO-HEALTH, or D-Health, and both the USPSTF and the Endocrine Society have issued recommendations reflecting that. Vitamin K2 has a well-established biochemical mechanism and genuinely contested trial results, with one three-year trial finding site-specific benefits and several equally rigorous trials finding none. What this means for us We sell a vitamin D3 and K2 product, and the evidence above complicates the case for it more than it supports it. Stating that plainly is the only defensible option. For D3, the honest position is that the fracture-prevention rationale does not hold up for generally healthy adults without deficiency, based on trials involving tens of thousands of participants and reflected in current guidance from two major bodies. Vitamin D still has a real physiological role in calcium absorption, deficiency is still worth correcting, and specific populations still warrant supplementation. But if the reason you are taking D3 is to prevent fractures and you are not deficient, the large randomized trials do not support that expectation. For K2, the position we have held across previous posts stands: promising mechanism, genuinely mixed trial results, not established. Anyone wanting to know their actual vitamin D status can have it measured, though it is worth noting that the Endocrine Society's 2024 guidance specifically discourages routine screening in healthy adults under 75, which is itself a signal about how the field now views population-wide vitamin D management. The honest summary Bone loss accelerates after menopause because estrogen's regulatory role in bone turnover diminishes. That is real and worth taking seriously. Vitamin D3 supplementation did not reduce fracture risk in VITAL, a trial of 25,871 participants, and the null result held even in those with lower baseline vitamin D levels. DO-HEALTH and D-Health corroborated it. The USPSTF issued a grade D recommendation against supplementation for primary fracture prevention in community-dwelling adults in 2024, and the Endocrine Society advises against empiric supplementation in healthy adults under 75. Vitamin K2 has a solid biochemical mechanism and contradictory trial results, with rigorous studies on both sides. Protein is the most improved story: the decades-long belief that it harms bone was overturned by Fenton and colleagues, and current expert consensus associates intake at or above 0.8 grams per kilogram with better bone outcomes, though randomized trials show no bone density difference and the positive findings are observational. And exercise, specifically weight-bearing and resistance training, remains the intervention with the most direct mechanism and the clearest role, both in loading bone and in reducing the falls that turn low density into fractures. That is a less supplement-friendly conclusion than most content on this topic reaches. It is what the trials found.
Learn more
Magnesium and Hormonal Change: What the Evidence Actually Supports
Magnesium and Hormonal Change: What the Evidence Actually Supports Magnesium is marketed for essentially every hormone-related complaint a woman might have: premenstrual symptoms, perimenopausal mood changes, hot flashes, cortisol regulation, thyroid function. The mechanistic reasoning offered is usually plausible, and the confidence of the claims is usually high. The clinical evidence does not match that confidence. In several of these areas it points the other way, and in at least one case the most frequently cited supporting study has a methodological problem that explains a great deal about why the result looked as good as it did. This post separates the mechanism from the outcomes, examines what the trials actually found, and identifies the one area where magnesium's evidence in this context is genuinely reasonable. It is a narrower conclusion than most content on this topic offers. The mechanism is real, and mechanism is not evidence Magnesium participates in a large number of physiological processes relevant to hormonal function. It influences GABA signalling, the brain's primary inhibitory neurotransmitter system. It plays a role in the regulation of the stress response, including pathways involving cortisol. It is involved in processes touching serotonin, norepinephrine, and thyroid-stimulating hormone. It is required for the enzymatic activity underlying a broad range of metabolic functions. All of that is accurate and none of it is in dispute. What it establishes is that magnesium could plausibly influence hormone-related symptoms. It does not establish that supplementing magnesium does influence them in a measurable, clinically meaningful way. That second question requires clinical trials, and this is precisely where the gap between marketing and evidence opens up. The distinction matters because mechanistic plausibility is abundant in nutrition science and frequently fails to translate. A compound can participate in a relevant pathway and still produce no detectable change in the outcome people actually care about, either because the pathway was not the limiting factor, or because supplementation does not shift it far enough to matter. Premenstrual symptoms: what the reviews concluded Premenstrual syndrome affects roughly 48 percent of women of reproductive age worldwide, and magnesium is one of the most commonly recommended nutritional interventions for it. The evidence base is worth examining directly. A systematic review of randomized controlled trials examining nutritional interventions for the psychological symptoms of premenstrual syndrome, published in Nutrition Reviews in 2025, volume 83, issue 2, reached a specific conclusion about magnesium. The review found insufficient evidence to support the effects of vitamin B1, vitamin D, whole-grain carbohydrates, soy isoflavones, dietary fatty acids, magnesium, multivitamin supplementation, or PMS-specific diets on psychological premenstrual symptoms. Magnesium appears in that list by name. This is a systematic review of randomized controlled trials concluding that the evidence for magnesium in this application is insufficient. There is one finding worth reporting alongside it, because it is more nuanced than a flat negative. The same review describes a randomized crossover study of 44 British women with PMS in which a daily combination of 200 milligrams of magnesium and 50 milligrams of vitamin B6, taken for one month, produced a significant decrease in anxiety-related symptoms including nervous tension, mood swings, irritability, and anxiety, compared with single nutrients or placebo, with a p-value of 0.04. Read that carefully. The combination outperformed single nutrients. Which means magnesium on its own, tested within the same study, did not produce the effect. The review's overall assessment of combined nutrient and multivitamin supplements for psychological PMS symptoms was that the evidence remains limited. A separate systematic review and meta-analysis of observational studies examining the association between serum magnesium levels and premenstrual syndrome, covering 13 studies, described the findings across the literature as inconclusive. For context on what better evidence in this area looks like: a systematic review and meta-analysis of randomized controlled trials examining exercise for premenstrual syndrome found reduced global PMS symptom scores with a standardized mean difference of negative 1.08 and a 95 percent confidence interval of negative 1.88 to negative 0.29. Even that result came with substantial heterogeneity at 87 percent and with 87 percent of included trials assessed at high risk of bias, leading the authors to conclude that exercise may be effective but some uncertainty remains. That is what a cautiously positive finding looks like in this field. The magnesium literature does not currently reach it. Menopause and hot flashes: the study that gets cited, and the problem with it This section requires more care than the last, because the commonly cited evidence looks stronger than it is for a specific and identifiable reason. The most frequently referenced study is a pilot phase II trial conducted at the Mayo Clinic and published by Park and colleagues in 2011, examining magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Participants took 400 milligrams of magnesium oxide at bedtime, increasing to 400 milligrams twice daily after two weeks if symptoms had not improved. The reported results were substantial: greater than 50 percent decreases in fatigue, distress due to hot flashes, and severity of abnormal sweating. Those are impressive numbers, and they are widely quoted. The trial was a phase II pilot. A subsequent larger randomized controlled trial, conducted as NCCTG N10C2 through the Alliance cooperative group and described as a double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes, found smaller effects than the pilot had suggested. The reason that pattern matters is specific to this symptom. Hot flashes are unusually responsive to placebo, and the evidence for this is direct rather than theoretical. A randomized sham-controlled trial testing acupuncture for menopausal hot flashes found that both the real acupuncture group and the sham group improved equally. The intervention and the convincing imitation of the intervention produced the same result. When a symptom responds that strongly to placebo, an uncontrolled or open-label pilot study will systematically overstate an intervention's effect, and the effect will shrink when a proper placebo control is introduced. That is precisely the pattern observed between the 2011 pilot and the larger controlled follow-up. This is not a criticism of the original researchers, who conducted a pilot study and labelled it as such. It is a criticism of how that pilot gets cited, frequently without the phase II designation and without the subsequent controlled trial that qualified it. It is also worth noting that the British Menopause Society does not currently list magnesium as a first-line treatment for menopausal symptoms. Magnesium L-threonate and menopause: the evidence gap stated by researchers Magnesium L-threonate is increasingly marketed for menopausal symptoms on the strength of its ability to cross the blood-brain barrier more effectively than other forms. The mechanistic argument is reasonable. The evidence specific to menopause is essentially absent, and this can be verified from an unusually direct source: the registration documents for a clinical trial currently investigating exactly this question. That trial registration states that randomized controlled trials involving magnesium L-threonate have only confirmed improvement effects on pain and cognitive function, and that research on its effect on improving overall menopausal symptoms is rare. That is researchers setting up a study to answer a question, stating plainly in their own trial documentation that the question has not yet been answered. Any product currently marketing magnesium L-threonate for menopausal symptoms is making a claim ahead of the evidence its own investigators acknowledge is missing. Cortisol and the stress response Magnesium's involvement in stress response regulation is frequently cited as a reason it should help with perimenopausal anxiety and stress reactivity. A systematic review examining the efficacy of magnesium supplementation for subjective measures of anxiety and stress noted that magnesium status is associated with subjective anxiety, which has led to the proposition that supplementation may attenuate anxiety symptoms. The review's assessment of the underlying literature was that the quality of some of the reviewed studies was questionable, and that well-designed randomized controlled trials are needed. Note the structure of that association claim as well. Magnesium status being associated with anxiety is an observational finding, and it runs in both directions: low magnesium could contribute to anxiety, or chronic stress could deplete magnesium, or an unmeasured third factor could drive both. Observational association does not establish that supplementing will reverse the relationship. Where the evidence is genuinely better There is one area where magnesium's evidence in this population holds up reasonably well, and it is worth identifying precisely because the rest of this post has been negative. Sleep. Around 60 percent of women in perimenopause and menopause report sleep disturbance according to NICE guidance, making it the most common complaint in this population. A randomized controlled trial published in the Journal of Research in Medical Sciences found that older adults taking 500 milligrams of magnesium daily for eight weeks fell asleep faster, slept longer, and showed higher melatonin levels compared to placebo. We have covered magnesium and sleep in detail elsewhere, including its limitations, and will not repeat that here. What is worth adding in this specific context is a distinction that usually gets collapsed. The sleep evidence is not hormone-specific. The trial above was conducted in older adults, not specifically in menopausal women, and the mechanism proposed, involving GABA activation and general nervous system calming, is not a hormonal mechanism. If magnesium improves sleep in perimenopausal women, the most likely explanation is that it improves sleep in people generally, and perimenopausal women are people who frequently have disrupted sleep. That is still useful. Sleep disruption is the dominant complaint in this population, and improving it would matter regardless of the mechanism. But it is a different claim than magnesium addressing hormonal change, and conflating the two makes the evidence look broader than it is. It is also worth noting the plausible indirect pathway: if magnesium improves sleep, and poor sleep worsens mood, stress reactivity, and the subjective burden of other symptoms, then downstream improvements could follow without magnesium acting on hormonal pathways at all. Several sources describing women's experience note that those who report hot flash improvement typically notice it alongside better sleep and reduced anxiety, which is consistent with a general nervous system effect rather than a direct hormonal one. What this adds up to The honest hierarchy for magnesium in the context of hormonal change looks like this. For sleep, the evidence is reasonable, the mechanism is plausible, and the relevance to this population is high given how common sleep disruption is. This is the strongest case and it is not a hormonal claim. For premenstrual psychological symptoms, a 2025 systematic review of randomized controlled trials found insufficient evidence for magnesium specifically, with one crossover study suggesting a magnesium and B6 combination may outperform either nutrient alone in a small sample. For hot flashes, the widely cited positive finding came from a phase II pilot, a larger placebo-controlled trial found smaller effects, and the symptom in question is documented to respond strongly to placebo, which explains the discrepancy. For cortisol and stress reactivity, the mechanistic involvement is real, the observational associations exist, and the intervention literature has been assessed as questionable in quality by the researchers reviewing it. For magnesium L-threonate and menopausal symptoms specifically, the investigators currently studying the question state in their own trial documentation that the research is rare. None of this means magnesium is not worth taking. Adequate magnesium intake matters for reasons well established independently of hormonal considerations, and a meaningful share of adults fall short of recommended intake from diet alone. Correcting a genuine shortfall is a reasonable thing to do. What it means is that the specific claim that magnesium addresses hormonal change is considerably less supported than the volume of marketing around it would suggest, and that the most defensible reason to take it in this context is the least glamorous one: sleep support, which is not a hormonal mechanism, in a population that happens to have a high prevalence of sleep disruption. The honest summary Magnesium participates in pathways relevant to hormonal function. That is mechanism, and mechanism is a hypothesis rather than a finding. The clinical evidence, examined directly: insufficient for premenstrual psychological symptoms according to a 2025 systematic review naming magnesium specifically. Promising in a phase II pilot for hot flashes, smaller in the larger controlled follow-up, in a symptom documented to respond strongly to placebo. Questionable in quality for anxiety and stress according to the review assessing it. Explicitly rare for magnesium L-threonate and menopausal symptoms according to researchers currently studying it. Reasonable for sleep, which is not a hormonal mechanism but is the most common complaint in this population. That is a narrower and less satisfying answer than the confident version circulating in this category. It is the one the published trials support, and it is the one worth making decisions on.
Learn more
Muscle Loss in Midlife: The Nutrition Side of the Conversation
Muscle Loss in Midlife: The Nutrition Side of the Conversation There is a framing problem with most content on this subject, and it is worth naming before anything else. Muscle loss in midlife gets discussed as a nutrition problem with a nutrition solution. Eat more protein, add the right supplements, and the decline slows. The research tells a different story, one where nutrition genuinely matters but occupies a supporting role rather than the leading one, and where the evidence for nutrition acting alone is considerably weaker than the marketing around it suggests. This post covers what the clinical research actually establishes: how muscle loss is defined and measured, what the real rates are, what nutrition contributes, and where the evidence stops. The honest version is more useful than the flattering one, particularly for anyone making decisions based on it. What is actually being measured The clinical term is sarcopenia, and its definition changed in a way that reveals something important about the condition itself. The European Working Group on Sarcopenia in Older People published its original diagnostic criteria in 2010, built primarily around low muscle mass. In 2019, the revised consensus, published as Cruz-Jentoft and colleagues in Age and Ageing, volume 48, issue 1, pages 16 to 31, made a significant change: it elevated low muscle strength to the primary diagnostic criterion, with muscle quantity serving as confirmation rather than the starting point. That shift was not arbitrary. It reflected accumulating evidence that strength predicts adverse outcomes better than mass does, and that the two do not decline at the same rate. Under EWGSOP2, the diagnostic pathway runs in stages. The SARC-F questionnaire, with a score of 4 or above, is used to identify people who may have sarcopenia. Grip strength and chair stand tests confirm low muscle strength. DXA and BIA are recommended for evaluating muscle quantity in usual clinical care, with DXA, MRI, or CT in research settings. Measures of physical performance, including the Short Physical Performance Battery, Timed Up and Go, and the 400-metre walk test, are used to assess severity. Severe sarcopenia is defined as poor physical performance alongside both low strength and low muscle quantity. Prevalence in community healthcare settings has been reported to reach up to 29 percent among older adults. The rates, and the detail most summaries miss EWGSOP2 describes muscle mass and strength as generally increasing through youth and young adulthood, reaching maximal levels up to roughly age 40, being maintained through midlife, and then declining with ageing. The specific figures cited in that consensus are worth reading carefully. Beyond age 50, reported losses run at 1 to 2 percent per year for leg muscle mass, and 1.5 to 5 percent per year for strength. Strength declines faster than mass. In some estimates, considerably faster. That asymmetry is the single most useful fact in this entire literature, and it gets almost no attention in consumer content. It means the thing you lose first, and fastest, is not size. It is the ability to produce force, which is what actually determines whether you can carry groceries up stairs, catch yourself when you stumble, or get out of a chair without using your arms. It also explains why EWGSOP2 reorganized its criteria around strength. If you monitor only muscle mass, you are tracking the slower-moving variable and missing the one more closely tied to function. Separately, multiple prospective studies have reported skeletal muscle mass decreasing by roughly 6 percent per decade after middle age, which is broadly consistent with the annual figures above. Where nutrition enters, and what it can actually do Here is where the evidence gets genuinely messy, and where honest reporting requires acknowledging contradictory findings rather than selecting the convenient ones. Protein without exercise. The results are inconsistent. Some clinical trials have found that diets providing 1.5 to 1.6 grams of protein per kilogram per day improved muscle mass without exercise, compared to diets providing 0.8 to 1.2 grams per kilogram, in older adults whose habitual intake sat around 0.8 to 1.1 grams per kilogram. Other work points the opposite direction. Tieland and colleagues found that protein supplementation of 0.41 grams per kilogram per day did not improve muscle mass without exercise when compared against an isocaloric placebo. A 2024 systematic review and meta-analysis examining dose, frequency, and timing of protein supplementation reported improved muscle mass gain from protein supplementation without exercise interventions, explicitly noting that this contradicted the findings of a recent earlier meta-analysis. So: the literature contains studies pointing both ways, and meta-analyses that disagree with each other. Anyone presenting protein-without-exercise as an established intervention for midlife muscle loss is describing a more settled field than exists. Protein with resistance training. This combination has stronger support, but the findings are more qualified than usually reported. A network meta-analysis of 38 randomized controlled trials involving 2,610 participants found that combining protein supplementation with resistance training significantly improved lean body mass compared to protein supplementation alone, with a standardized mean difference of 0.44 and a 95 percent confidence interval of 0.05 to 0.95. But the same analysis found no differences on any outcome when comparing the combined treatment against resistance training alone. Adding protein to a resistance training program did not outperform the training program by itself. The authors described the effects of combining protein supplementation and resistance training in healthy older adults as remaining largely controversial. A separate systematic review and meta-analysis specifically examining whey protein supplementation during resistance exercise training in older people with sarcopenia did find whey more effective than training alone for handgrip strength and skeletal muscle mass. The authors then qualified that finding directly: the effect sizes were small, the mean difference did not exceed the minimally important clinical difference, and the quality of evidence was rated low to very low under the GRADE framework. That is a research team reporting a positive result and then telling readers not to over-interpret it. Worth respecting rather than skipping past. The strongest combined finding. A network meta-analysis covering 96 studies and 7,596 participants found that resistance and balance training combined with protein-based nutritional supplementation was the most effective intervention across multiple outcomes: grip strength improved by a mean difference of 5.45 kilograms, gait speed by 0.20 metres per second, Short Physical Performance Battery score by 3.59 points, and skeletal muscle index by 0.95 kilograms per square metre. Note the structure of that finding. The winning intervention is training plus nutrition. Nutrition appears as a component of the most effective approach, not as the approach itself. Creatine, reported honestly Creatine has the most specific recent evidence in this population, and the numbers deserve to be reported with their confidence intervals rather than summarized as a positive result. A systematic review and three-level meta-analysis examining resistance training combined with creatine supplementation in older adults found that creatine plus resistance training significantly improved muscle strength compared to resistance training alone, with a Hedges' g of 0.31 and a 95 percent confidence interval of 0.18 to 0.45. The certainty of evidence for that outcome was rated moderate. The other two outcomes did not reach statistical significance. Muscle mass showed a pooled effect of 0.35 with a confidence interval of negative 0.09 to 0.78, rated low certainty. Physical function showed 0.47 with a confidence interval of negative 0.08 to 1.03 and a p-value of 0.086, rated very low certainty. So the honest summary for creatine in older adults: a small but statistically robust benefit for strength when added to resistance training, with moderate-quality evidence. No statistically significant effect on muscle mass or physical function in this analysis. Moderator analyses did not identify creatine dose, loading phase, intervention duration, training frequency, training intensity, sex, or testing site as stable sources of variation in the effect. A small strength benefit with moderate certainty is a genuinely reasonable thing to pursue. It is not the same claim as creatine preventing age-related muscle loss, and the difference matters. The hierarchy the evidence actually supports Putting this together produces a clear ordering, and it is not the ordering supplement marketing implies. Resistance training is the primary intervention. It appears in every effective protocol in this literature. Where nutrition has been tested against it head to head, training alone frequently matches combined approaches. Where combined approaches win, training is the component doing the heavy lifting. Adequate protein is the necessary foundation, not the active lever. Protein supports the adaptive response to training. In the absence of training, its independent effect on muscle mass is inconsistent across the literature and disputed between meta-analyses. Creatine is a modest, evidence-supported addition to a training program, with a small but reasonably certain benefit for strength specifically. Other nutritional interventions, including omega-3 fatty acids and vitamin D, have been examined in this population with mixed and generally smaller effects. A systematic review and meta-analysis of omega-3 supplementation with or without resistance training in older adults, covering 16 studies and 2,438 participants, found effects that were inconsistent across measures. What this hierarchy means practically: if you are not doing resistance training, changing your protein intake is unlikely to be the deciding factor in your muscle trajectory. If you are doing resistance training, adequate protein makes that training more productive, and creatine adds a small increment on top of that. Why midlife specifically EWGSOP2 places peak muscle mass and strength at around age 40, with maintenance through midlife and decline thereafter. The measurable acceleration in the figures cited above begins beyond age 50. Midlife is therefore not when the decline is steepest. It is when the trajectory is being set. The muscle mass and strength you carry into your 50s and 60s determines how much you can afford to lose, and resistance training adaptations come more readily before anabolic resistance becomes pronounced than after. That is the honest case for paying attention at 40 to 50: not that requirements have changed dramatically, but that the intervention with the strongest evidence, resistance training, is easier to start and more productive now than it will be later. What is worth doing with this The practical implications follow directly from the hierarchy. Resistance training deserves the largest share of attention and effort, because that is where the evidence concentrates. Two to three sessions per week involving progressive loading is the intervention that appears in essentially every effective protocol in this literature. Adequate protein supports that training rather than substituting for it. The PROT-AGE and ESPEN recommendations of 1.0 to 1.2 and 1.0 to 1.5 grams per kilogram per day respectively are directed at adults over 65, and distribution across meals may matter as much as the daily total, given that muscle protein synthesis reaches a plateau at roughly 0.40 grams per kilogram per meal in older adults compared to 0.24 in younger adults. Creatine at standard doses is a reasonable addition alongside training, with realistic expectations set by the effect sizes above. And if you want to track whether any of this is working, strength measures are more informative than scale weight or body composition estimates, for the same reason EWGSOP2 made strength its primary criterion. Grip strength and chair stand performance are both measurable at home, change faster than mass, and correspond more closely to the function that actually matters. The honest summary Muscle loss in midlife is real, measurable, and clinically defined. Strength declines faster than mass, at roughly 1.5 to 5 percent per year beyond age 50 compared to 1 to 2 percent for leg muscle mass, which is why the current diagnostic consensus was reorganized around strength rather than size. Nutrition is one side of this conversation, and it is the smaller side. The evidence for protein supplementation without exercise is genuinely contradictory, with meta-analyses reaching opposing conclusions. The evidence for protein alongside resistance training is better but qualified, with one large network meta-analysis finding no advantage over resistance training alone and a sarcopenia-specific review reporting small effects that did not exceed the minimally important clinical difference, at low to very low evidence quality. Creatine plus resistance training produces a small, moderate-certainty benefit for strength, with no statistically significant effect on mass or physical function in the most recent three-level meta-analysis. Resistance training is the intervention with the strongest evidence. Nutrition makes it work better. Presenting it the other way around would be easier to sell and harder to defend, and the research does not support it.
Learn more